



PRIZES PRIX GALIEN

Stanley T. Crooke, MD, PhD
n-Lorem Foundation
Founder, Chief Executive Officer and Chairman of the Board
2888 Loker Avenue East, Ste. 110
Carlsbad, CA 92010

July 27, 2022

PR ELIE WIESEL*
Honorary Founding President
Peace Nobel Laureate, Boston University

* *In Memoriam*

GALIEN AWARDS COMMITTEE 2022

PR SUSAN DESMOND-HELLMANN, M.D., M.PH.
Former Chief Executive Officer of the Bill & Melinda
Gates Foundation, Seattle, WA
Committee Chair

PR RICHARD AXEL, M.D.
Nobel Laureate, Co-director, the Kavli Institute for Brain
Science, Columbia University Medical Center, New York

PR LINDA BUCK, PH.D.
Nobel Laureate; Fred Hutchinson Cancer Research Center
member and Professor of Physiology and Biophysics,
University of Washington

PR LAURIE GLIMCHER, M.D.
President and CEO Dana Farber, Cancer Institute;
Professor of Medicine, Harvard Medical School

PR MARY-CLAIRE KING, PH.D.
American Cancer Society Professor of Genome Sciences
and Medical Genetics, University of Washington

PR ROBERT S. LANGER, M.D.
David H. Koch Institute Professor
at Massachusetts Institute of Technology

PR CATO T. LAURENCIN, M.D., PH.D.
University Professor, University of Connecticut

PR STEVEN LESTER, M.D.
Chief Medical Officer, Mayo Clinic-ASU MedTech
Accelerator

PR MICHAEL ROSENBLATT, M.D.
Senior Partner of Flagship Pioneering,
Cambridge, MA

PR MARC TESSIER-LAVIGNE, PH.D.
President, Stanford University, Stanford, CA

Dear Dr. Crooke,

We are very happy to notify you that you have been chosen by the Galien Awards Committee to receive the 2022 Roy Vagelos Pro Bono Humanum Award for Global Health Equity of the Prix Galien USA. Our independent Committee annually selects an individual or institution that has helped to improve the human condition in extraordinary ways.

In offering this recognition, our Committee of distinguished scientists and Nobel laureates cite your nearly 50 years of dedication to a novel, clinically endorsed concept of using synthetic oligonucleotides to control the expression of genes and proteins that impact disease. Your singular dedication to this RNA-driven antisense platform provided a new, highly personalized pathway to resolving some of the most difficult biomedical challenges, with the ultimate potential of treating multiple infections, inflammatory conditions and cancers targeted to individual patient profiles and with minimal side-effects. Due to your years of effort as a researcher, corporate R&D executive, biotech innovator and philanthropist, nearly a dozen antisense oligonucleotides (ASO) have been approved for clinical use since 1998; additional clinical trials focused in high unmet medical need areas like neuroscience are underway.

You are also recognized for your leadership in being among the first in industry to make a commitment to open science a key element of the modern R&D enterprise and to embrace the principle that even patients with the rarest of afflictions deserve the best talent and expertise our R&D industry can offer. Untold thousands of patients formerly with no hope of a cure stand to benefit from your belief in the promise of this entirely new class of medicines.

Enclosed for your information is the Prix Galien USA pamphlet listing the Awards Committee and past Pro Bono Humanum Award recipients, including Presidents Clinton and Carter in the presence of Professor Elie Wiesel, Honorary Founding President of the Galien Foundation, who took great pride in personally presenting this award and attended all ceremonies for this purpose until his death in 2016.

We shall be honored to welcome you on **October 27, 2022 at 7:30 pm** at our Ceremony in the American Museum of Natural History in New York to accept this award and deliver a keynote address to our audience of 700, including Nobel Laureates, researchers, U.S. policy-makers, and top executives from across the life sciences and medical technology industry.

Kindly note that this award is contingent on your personal acceptance and on-site participation on October 27th.

Our warmest congratulations and best wishes.

Very Respectfully,

Sue Desmond-Hellmann
Committee Chair

Bruno Cohen
Chairman